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Transthyretin-associated familial amyloid polyneuropathy (TTR-FAP) is a 
neurological disease that affects severely patients and their families and caregivers 
over generations. It is a rare, progressive, and if untreated fatal autosomal dominant 
hereditary disorder. The disease may affect multiple organ systems and if untreated 
progress rapidly to death. TTR-FAP affects nearly 10,000 people worldwide, with 
known endemic regions in Portugal, Sweden, and Japan. Until recently only liver 
transplantation and tafamidis were treatment options across several world regions. 
Despite the worldwide use of these disease-modifying treatments to delay disease 
progression, challenges in clinical assessment and management remain because of 
disease heterogeneity, phenotypic diversity, small patient populations, incomplete 
natural history and uncertainty of treatment effect in survival. The two new 
treatment options (inotersen and patisiran) appear to provide important benefits 
for patients, based on clinical trials short-term evidence. In this review, we discuss 
the disease natural survival course and currently available treatments impact on 
survival. We also discuss the importance of treatment choice (and or sequence 
of treatments) to maximize survival, while preserving the patient’s health-related 
quality of life.
IntroductionTransthyretin-associated familial amyloid polyneuropathy (TTR-FAP) is an autosomal-dominant, adult-onset, progressive neurodegenerative 
systemic disease, first identified by Corino de Andrade in Portugal1. TTR-FAP symptoms stem from amyloidosis that results from misfolding of the 
transthyretin (TTR) protein tetramer, leading to TTR fibrils and other aggregates2-5. More than 120 TTR gene mutations have been described, the most common of which associated with TTR-FAP is Val30Met6. The disease is rare; it affects 8000 to 10,000 people worldwide, with the endemic group of patients mainly found in Portugal, Sweden, and Japan7-9. Both sexes are affected, the disease onset occurs mainly in young adulthood (median 33 years age) and if untreated, it progresses rapidly to death, usually within 10 years after symptom onset, depending on the endemic region, genotype, symptoms, and other factors2. Common causes of death among untreated patients include cachexia, cardiac failure, arrhythmia and secondary infections10,11. The disease imposes a 
substantial burden characterized by high levels of patient´s impairment in physical health, quality of life, reduced productivity and a negative impact on the mental health of families and caregivers12.
Liver transplantation (LTx) was first implemented in 1990 as a surgical treatment option to halt or ameliorate familial TTR amyloidosis13. 
Because 95% of plasma TTR is of hepatic origin, LTx substantially reduces 
the concentration of mutant TTR in the blood14,15. Despite the benefits of LTx, improved survival is attained at the expense of long waiting times for 
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an organ, lifelong immunosuppressive therapy, significant early mortality, and postoperative complications which can impact long-term health-related quality of life16-19. 
Causes of death after LTx include secondary to septicaemia (22%), cardiovascular-related deaths (22%), liver-related complications (14%) and intraoperative death (3%)17. 
Also, in some cases, polyneuropathy has been reported to progress after LTx20.
Diflunisal is a non-steroidal anti-inflammatory drug (NSAID) developed in the 1970s. In Europe, the drug is not 
generally available and has occasional authorization use 
on a country basis. A randomized multicentre, placebo-
controlled phase 3 study confirmed that diflunisal at a dose of 250 mg twice daily slows the progression of the neuropathy21. However, the safety concerns with long-term NSAIDs use may limit its use in real world clinical setting among TTR-FAP patients22.Tafamidis, an oral, potent and selective TTR kinetic 
stabiliser that slows tetramer dissociation and amyloid 
genesis became available as a treatment option at 20 mg 
once daily, first in the context of clinical trials (2007) and 
later as an approved drug (November 2011 in the European Union) for the treatment of adult TTR-FAP patients in stage 1 to delay disease progression23,24. Tafamidis is currently the standard of care25; disease progression delay, quality of life preservation, nutritional status improvement and 
a favourable safety profile in long-term use has been demonstrated26-30. Most common adverse effects (≥1/10) in tafamidis-treated patients include urinary tract infections, 
vaginal infections, upper abdominal pain, and diarrhoea. Two new treatment options were recently approved for the treatment of adult patients in stage 1 or stage 2 transthyretin amyloid polyneuropathy disease31,32. 
Inotersen, a 2′-O-methoxyethyl–modified antisense 
oligonucleotide, inhibits hepatic production of 
transthyretin. Treatment with subcutaneous inotersen 300mg once weekly improved the course of neurologic 
disease and quality of life compared with placebo. 
Nevertheless, thrombocytopenia and renal dysfunction (including glomerulonephritis) are important safety concerns, managed with enhanced monitoring31. Patisiran, an RNA interference therapeutic delivered via 
intravenous infusion, specifically inhibits hepatic synthesis of transthyretin. This treatment (0.3 mg per kilogram of 
body weight, once every 3 weeks) significantly improved multiple clinical manifestations of hereditary transthyretin 
amyloidosis including significant improvements in neuropathy, quality of life, walking, nutritional status, and 
activities of daily living as compared with placebo. The most commonly reported adverse events in patisiran-treated patients included peripheral edema and infusion-
related reactions. Notably, the polyneuropathy disability score improved in some (8%) patients which included 
the transition from assisted to unassisted walking, an outstanding outcome for patients consistent with the effect of the medicine on gait speed32,33.  In the present work, we review the TTR-FAP disease 
natural course and currently available treatments impact 
on survival. We also reflect on treatment choice (and 
sequence of treatments), given the available treatments and the newly approved medicines. The clinical aim is to 
stabilize/halt disease progression in all possible patients, including those in more advanced stages, hence decreasing the disease excess mortality.
Literature Review
We searched Medline and Embase (Ovid interface), 
with the search terms “transthyretin*” OR (“amyloid* 
AND [family* OR heredit*]) combined with the terms 
“polyneuropathy” OR “neuropathy*” for the definition of the population (transthyretin-associated familial amyloid 
polyneuropathy [TTR-FAP]). The terms “natural history”, 
“survival”, and “mortality” were used for the definition of the outcomes of interest. To increase sensitivity, search terms 
were used as both indexed and free-text terms, without any language or type of study restrictions. After deduplication, a total of 455 references were independently screened to 
identify potential studies characterizing the natural history of TTR-FAP and evaluating the effect of treatment on the natural history (survival) of the disease.
Limited number of studies report the natural history of TTR-FAP and treatment impact, particularly as it relates to survival and its determinants. In the largest 
cohort study published, 3160 consecutive Portuguese 
patients with Val30Met were followed up since the first patient presentation34. The natural history of the disease 
was characterized by a median overall survival (mOS) of 12 years, with men and patients with late-onset disease 
facing significantly worse prognosis and a lower survival, if untreated. The median overall survival in the LTx cohort was 21 years since transplantation (maximum follow-up, 25 years). The median overall survival in the tafamidis 
cohort has not been reached, as the maximum follow-
up for this cohort was 10 years. In both treated cohorts, the mortality risk was higher among patients with longer 
disease duration before treatment initiation. The 10-year 
survival rates for the most recent LTx subgroup (year 2007 and onwards) and tafamidis-treated cohorts were 85% and 93%, respectively. In comparison with the untreated cohort 
of patients, both LTx and tafamidis significantly improved survival in stage 1 Val30Met patients with early-onset (<50 years) disease, with 75% and 91% reductions in mortality risk, respectively. Among this population, tafamidis was 
associated with significant survival gains compared with LTx, a 63% reduction in mortality risk. However, nearly 11% of tafamidis-treated patients have undergone posterior 
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LTx. Some authors argue that early-stage patients should 
be treated initially with tafamidis, and only undergone LTx if their disease progressed while on oral treatment35. 
On the other hand, other authors found this treatment 
strategy questionable17 because the patient prognosis 
would be worse for liver transplantation. In the Portuguese survival study this treatment sequence strategy was studied and it was found that previous tafamidis treatment did not worsen the survival prognosis for patients who later underwent LTx as compared with LTx treatment only, 
which can be very relevant for medical treatment sequence 
decision. For older late-onset patients (≥50 years) LTx is not a general treatment option, hence only tafamidis was compared with an untreated cohort. Among patients with late-onset disease tafamidis was associated with a 
significant 82% reduction in mortality risk. Early onset of disease, shorter disease duration, and tafamidis treatment 
were found to be independent favourable and significant factors for survival. 
We found two other studies characterizing the natural course of the disease which evaluated the effect of treatment (LTx) on survival. The Sweden survival study included 141 Val30Met patients (LTx, 108; untreated, 33) and has 
shown that patients who underwent LTx had significantly increased survival rate compared with untreated patient. 
Untreated patients had a median overall survival (mOS) of 12 years and 10 and 15 year survival rates of 62% and 19%, respectively. Patients who underwent LTx had 10 and 15 year survival rates of 83% and 60%, respectively. The study of 80 consecutive Japanese Val30Met patients (LTx, 37; untreated, 43) found similar outcomes for the untreated cohort37. Untreated patients had a mOS of 10 years (10-year survival rate of 56%), and LTx-treated patients had prolonged survival compared with untreated 
patients. Notably, this study classified deaths as either related or unrelated to progressive amyloidosis and reported an outstanding 100% survival rate at 10 years among LTx treated patients (n=37). The different approach 
followed on this study on how to analyze deaths can lead 
to completely different survival results. The reason being 
because LTx per se (not related to progressive amyloidosis) is associated with an early excess mortality. The Portuguese study evaluated all-cause mortality and  reported a 14% 
mortality rate in the first year following LTx, similar to what was found in the Swedish LTx cohort (n=108) and 
to what has been reported using data from the Familial Amyloidosis Polyneuropathy World Transplant Registry (FAPWTR)17. The FAPWTR retrospectively reported a noteworthy improvement in overall survival among LTx cohort (20-year survival rate of 55.3%) as compared with studies on the natural history of the disease38-40. In this 
study, higher modified body mass index, early onset of disease (<50 years of age), shorter disease duration, and TTR Val30Met rather than non-TTR Val30Met mutations in 
patients were independent favourable, significant factors for survival. Some variants such as Thr60Ala and Ile107Val are associated with a more rapid and severe disease progression41 as compared to Val30Met patients, and have a shorter median survival42.
Conclusion
Observational studies are of exceptional usefulness in 
the context of rare diseases such as TTR-FAP because they allow investigating questions unaddressed by randomized clinical trials and are of key importance for health policy 
and medical decision making. Our review has found that 
both LTx and tafamidis are associated with statistically 
significant and clinically relevant survival gains. Notably, tafamidis is associated with higher patient survival rates 
than LTx; although the follow-up has been relatively 
short (as compared with LTx follow-up) for definitive 
conclusions to be drawn. As anticipated due to their novelty, no evidence was found for survival among patients treated with inotersen or patisiran. Altogether, this evidence shows that the prognosis for patients with TTR-FAP has changed dramatically in the past 25 years, from a progressive, devastating, fatal disease to a more chronic condition with treatment leading to delayed disease progression and life expectancy gains. Improvements may 
be made in the prognosis of patients being timely diagnosis and early treatment initiation key aspects. However, not all 
patients are eligible for LTx or tafamidis treatment. Recent 
outstanding advances have been made in therapeutic treatment options which are much less invasive than LTx 
and appear to provide important benefits for patients. Longer follow-up data may facilitate understanding of how clinical practice can reach optimal treatment choice 
and sequence to maximize survival, while preserving the patient’s health-related quality of life.
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